Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow

被引:14
作者
Zhao, Xiaohui
Huang, Qin
Slovak, Marilyn
Weiss, Lawrence
机构
[1] UCI, Med Ctr, Dept Pathol, Orange, CA 92868 USA
[2] City Hope Natl Med Ctr, Duarte, CA 91010 USA
关键词
bone marrow; plasma cell myeloma; residual disease; ancillary studies;
D O I
10.1309/B2P9XEH44CY9LPUK
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Morphologic determination of residual plasma cell myeloma is often difficult. This study was conducted to evaluate the diagnostic value of several ancillary methods. A total of 121 bone marrow specimens from patients with myeloma after bone marrow, transplantation or chemotherapy were studied. Of those, 49 cases were studied by conventional cytogenetics (CC), 86 by flow cytometry (FC). 50 by immunohistochemical analysis, 72 by molecular studies (MS)for immunoglobulin gene rearrangements. and 18 by standard fluorescence in situ hybridization (FISH) study. Of the patients, 70 were found to have residual myeloma. Residual disease was detected in 58 of 70 patients by morphologic examination (detection rate, 83%), 25 of 26 by immunohistochemical analysis (96%), 39 of 54 by FC (72%). 6 of 40 by CC (15%), 6 of 12 by FISH (50%), and 24 of 40 by MS (60%). Among the ancillary studies, immunohistochemical analysis and FC were the most helpful ancillary studies for detection of residual disease in myeloma. with immunohistochemical analysis the most effective single method.
引用
收藏
页码:895 / 904
页数:10
相关论文
共 30 条
[1]   High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma [J].
Almeida, J ;
Orfao, A ;
Ocqueteau, M ;
Mateo, G ;
Corral, M ;
Caballero, MD ;
Blade, J ;
Moro, MJ ;
Hernandez, J ;
San Miguel, JF .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (01) :121-131
[2]   Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation [J].
Avet-Loiseau, H ;
Facon, T ;
Grosbois, B ;
Magrangeas, F ;
Rapp, MJ ;
Harousseau, JL ;
Minvielle, S ;
Bataille, R .
BLOOD, 2002, 99 (06) :2185-2191
[3]   CYTOPLASMIC IMMUNOGLOBULIN CONTENT IN MULTIPLE-MYELOMA [J].
BARLOGIE, B ;
ALEXANIAN, R ;
PERSHOUSE, M ;
SMALLWOOD, L ;
SMITH, L .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (02) :765-769
[4]   Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: Shed syndecan-1 accumulates in fibrotic regions [J].
Bayer-Garner, IB ;
Sanderson, RD ;
Dhodapkar, MV ;
Owens, RB ;
Wilson, CS .
MODERN PATHOLOGY, 2001, 14 (10) :1052-1058
[5]  
Billadeau D, 1996, BLOOD, V88, P289
[6]  
Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x
[7]   A novel multiparametric approach for analysis of cytoplasmic immunoglobulin light chains by flow cytometry [J].
Chang, CC ;
Schur, BC ;
Kampalath, B ;
Lindholm, P ;
Becker, CG ;
Vesole, DH .
MODERN PATHOLOGY, 2001, 14 (10) :1015-1021
[8]   Incidental and concurrent malignant lymphomas discovered at the time of prostatectomy and prostate biopsy - A study of 29 cases [J].
Chu, PGG ;
Huang, Q ;
Weiss, LM .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (05) :693-699
[9]   Molecular and clinical remissions in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells [J].
Corradini, P ;
Voena, C ;
Tarella, C ;
Astolfi, M ;
Ladetto, M ;
Palumbo, A ;
Van Lint, MT ;
Bacigalupo, A ;
Santoro, A ;
Musso, M ;
Majolino, I ;
Boccadoro, M ;
Pileri, A .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (01) :208-215
[10]   Minimal residual disease monitoring in multiple myeloma [J].
Davies, FE ;
Rawstron, RC ;
Owen, RG ;
Morgan, GJ .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2002, 15 (01) :197-222